Resources from the same session
Randomized, open-label, phase III study comparing irinotecan plus S-1 with S-1 alone in patients with advanced esophageal squamous cell carcinoma after failure of prior platinum- or taxane-based chemotherapy: Results of an interim analysis
Presenter: Jing Huang
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (LAPC): Final analysis of JCOG1106
Presenter: Tatsuya Ioka
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Prognosis, efficacy, and safety by liver disease etiology
Presenter: Takuji Okusaka
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Prognostic factors in curative treatment of gallbladder cancer - Data of 950 cases of “The German- Registry”
Presenter: Thorsten Goetze
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Phase III study comparing intraperitoneal paclitaxel plus S-1/paclitaxel with S-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial
Presenter: Yoshiyuki Fujiwara
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Molecular characteristics of hepatocellular carcinomas (HCC) from different age groups
Presenter: Celina Ang
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Invited discussant abstracts LBA26, LBA27 and 616PD
Presenter: Eric Van Cutsem
Session: Gastrointestinal tumours, non-colorectal
Resources:
Presentation
Invited discussant abstracts 617PD, 618PD, 619PD and LBA28
Presenter: Florian Lordick
Session: Gastrointestinal tumours, non-colorectal
Resources:
Presentation
Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
Presenter: Li-Tzong Chen
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial
Presenter: Jordi Bruix
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract